On this page
How should CTD 3.3 literature references support the quality dossier?
Include the key literature actually relied on in the quality narrative, with enough identity and location information to retrieve it. Check that the source supports the cited claim for the relevant material and conditions. A complete reference list is a navigation aid; it does not establish that the underlying scientific inference is sound.
Before you begin
M4Q(R1) 3.3 for key cited literature where applicable. Literature is not a substitute for product-specific evidence when that evidence is needed.
What you will prepare: A reconciled reference package with accurate citations and scoped links from the quality narrative.
Work outward from claims in S, P, A and R
M4Q identifies 3.3 as the location for key referenced literature, if applicable. Build the inventory from the actual quality narrative rather than attaching a generic reading list. Record title, authors, publication details, stable identifier where available, and the section/claim relying on the source. Check the full article and any relevant supplement, correction or retraction status through the publisher or authoritative record.
Distinguish an original experimental publication from a review that merely cites it. Use a precise reference for the evidence being relied upon and avoid presenting an abstract as if the complete methods and results were reviewed. These checks are editorial best practices for a defensible evidence trail.
Explain the boundary of what a publication establishes
Compare the published material, route, formulation, method and conditions with the dossier's actual context. Where the narrative uses literature to support a rationale, explain the relevant similarity and limitation. A paper about a different polymorph or container material cannot silently support a product-specific conclusion.
Fictional exercise: P.2 cites a publication as proof of compatibility, but the study used another excipient grade at a different pH. Ask the formulation owner whether the paper supports only background rationale or whether additional product-specific evidence is needed. Revise the claim to match that conclusion and link the actual supporting studies. Do not repair the mismatch by citing more review articles.
Reconcile the files, citations and reader navigation
Check that every included reference is cited where it is used and that every consequential literature citation has an identifiable source. Preserve the actual document version and include the relevant supplementary material when it is part of the evidence, using authorized copies and the applicable publishing process. Do not invent a downloadable attachment that has not been supplied.
At handoff, inspect titles and identifiers in the published output and test the links or bookmarks the publisher creates. If a source is unavailable, record the gap and qualify the dependent claim rather than stating that it was verified. Reference-list completeness is a navigation check; the scientific adequacy of the cited evidence remains a separate review.
Review citation identity and scientific relevance separately
Build this editorial register from the claims in S, P, A and R. Starting from a folder of papers can produce an impressive bibliography without demonstrating why those papers belong in the dossier.
| Review layer | Record to inspect | Question to answer |
|---|---|---|
| Source identity | Title, authors, publication details and stable identifier | Is this the work actually cited? |
| Exact support | Relevant passage, result, method and supplement | Does it support this particular claim? |
| Applicability | Material, formulation, route and experimental conditions | What is similar, different or uncertain? |
| Publication status | Relevant correction or other authoritative notice | Is the cited interpretation still represented accurately? |
| Submission navigation | Cited location and supplied copy relationship | Can the reviewer find the intended evidence? |
Review exercise: a review article mentions an experiment, but the dossier states the numerical finding as though the original methods were inspected. Obtain the original work where needed, verify the number and context, and qualify any access limitation. Adding more secondary citations does not repair an unverified exact claim.
For product-specific conclusions, ask the scientific owner to explain what the publication can support and what still relies on the applicant's evidence. A study with another excipient grade may inform a development rationale without establishing compatibility for the proposed formulation.
Reconcile the final references with P.2 development and S.3 characterization, where literature often contributes to an argument. Keep unavailable sources visible as review issues instead of fabricating a verified retrieval status.
Your preparation checklist
0/3 checkedUse this to track your review in this visit. Checks are not saved and do not establish regulatory compliance.
Frequently asked questions
Should 3.3 contain a general reading list about the product?
Build the section around key literature referenced by the quality dossier, rather than a general reading list. Connect each included work to the claim or rationale using it. A large bibliography does not make an unsupported product-specific conclusion more defensible.
Does a working DOI prove that a citation supports the claim?
No. It establishes a route to a publication, not the validity of the inference. Inspect the relevant content, methods and conditions and compare them with the dossier claim. A correctly identified paper can still concern a different material or answer a different question.
Can published compatibility data replace every product-specific study?
Do not assume that relationship. Compare the published material and conditions with the actual formulation and proposed use, then obtain the scientific assessment of what the literature supports. It may provide background rationale without establishing the complete product-specific conclusion.
Sources and revisions
Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.
Guidance
ICH M4Q(R1): CTD Quality ↗Step 4, September 12, 2002; Module 3, printed pages 5–18. Organization/content guidance, not a universal list of required studies. Checked September 22, 2026. Guide-specific passages: 3.3, printed page 18.
Technical specification · placement only
FDA eCTD v4.0 comprehensive hierarchy ↗Version 2.2, February 2025. Section 3.3. A heading identifies placement, not mandatory applicability.

